101 related articles for article (PubMed ID: 1966283)
1. Calcium metabolism in premenopausal women treated by a Gn-RH agonist for uterine myoma.
Ito M; Sakoda Y; Okamura H
Endocrinol Jpn; 1990 Dec; 37(6):907-13. PubMed ID: 1966283
[TBL] [Abstract][Full Text] [Related]
2. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
Nakamura Y; Yoshimura Y; Yamada H; Ubukata Y; Ando M; Suzuki M
Fertil Steril; 1991 May; 55(5):900-5. PubMed ID: 1902420
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata.
Franssen AM; Willemsen WN; Corbey RS; Doesburg WH; van 't Veen AJ; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(3):221-8. PubMed ID: 1908799
[TBL] [Abstract][Full Text] [Related]
4. [Bone mineral content in premenopausal women treated with gonadotropin-releasing hormone analogue].
Masahashi T; Negoro Y; Asai M; Suzuki M; Noguchi M; Nakanishi M; Tomita A
Nihon Sanka Fujinka Gakkai Zasshi; 1992 May; 44(5):577-80. PubMed ID: 1619317
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of urinary CrossLaps as a sensitive marker of bone metabolism.
Nakayama H; Yano T; Sagara Y; Ando K; Kasai Y; Taketani Y
Endocr J; 1997 Aug; 44(4):479-84. PubMed ID: 9447279
[TBL] [Abstract][Full Text] [Related]
6. Differential reduction in the volume of leiomyoma and uterus during buserelin treatment.
Puzigaća Z; Prelević GM; Sretenović Z
Gynecol Endocrinol; 1994 Mar; 8(1):39-43. PubMed ID: 8059616
[TBL] [Abstract][Full Text] [Related]
7. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.
Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G
Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152
[TBL] [Abstract][Full Text] [Related]
8. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women.
Matta WH; Shaw RW; Hesp R; Evans R
Clin Endocrinol (Oxf); 1988 Jul; 29(1):45-51. PubMed ID: 3150319
[TBL] [Abstract][Full Text] [Related]
9. Calcium homeostasis, bone metabolism and safety aspects during long-term treatment with a GnRH agonist.
Eckstein N; Foldes J; Feinstein Y; Vagman I; Eshel A; Steinberg R; Statter M; Limor R; Ayalon D
Maturitas; 1992 Aug; 15(1):25-32. PubMed ID: 1388219
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
Matta WH; Shaw RW; Nye M
Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of leiomyomas with luteinizing hormone-releasing hormone agonist].
Nakamura Y; Yoshimura Y; Yamada H; Maruyama K; Nanno T; Ubukata Y; Ando M; Takahashi K; Suzuki M
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec; 42(12):1620-6. PubMed ID: 2126024
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone mineral content following hormone treatment for endometriosis.
Fukushima M
Int J Gynaecol Obstet; 1995 Sep; 50 Suppl 1():S17-22. PubMed ID: 8529770
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects on bone mineral density and bone metabolism of 6 months' treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate.
Makita K; Ishitani K; Ohta H; Horiguchi F; Nozawa S
J Bone Miner Metab; 2005; 23(5):389-94. PubMed ID: 16133689
[TBL] [Abstract][Full Text] [Related]
14. Treatment of symptomatic uterine leiomyoma with letrozole.
Gurates B; Parmaksiz C; Kilic G; Celik H; Kumru S; Simsek M
Reprod Biomed Online; 2008 Oct; 17(4):569-74. PubMed ID: 18854113
[TBL] [Abstract][Full Text] [Related]
15. Experience with leuprorelin acetate depot in the treatment of fibroids: a German multicentre study.
Cirkel U; Ochs H; Schneider HP; Mettler L; Mayer-Eichberger D; Schindler AE; Bühler K; Winkler U; Zahradnik HP; Künzig HJ
Clin Ther; 1992; 14 Suppl A():37-50. PubMed ID: 1606593
[TBL] [Abstract][Full Text] [Related]
16. [Shrinkage of uterine leiomyomas after intranasal administration of a LHRH agonist].
Uemura T; Kimura A; Shirasu K; Minaguchi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Mar; 41(3):365-8. PubMed ID: 2499643
[No Abstract] [Full Text] [Related]
17. Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study.
Imai A; Matsunami K; Ichigo S; Takagi H
Gynecol Endocrinol; 2016; 32(3):250-2. PubMed ID: 26503621
[TBL] [Abstract][Full Text] [Related]
18. Uterine leiomyoma and LHRH agonist treatment. A preliminary report.
Rolland R; Franssen AM; Willemsen WN; Corbey RS
Prog Clin Biol Res; 1986; 225():313-20. PubMed ID: 3097670
[No Abstract] [Full Text] [Related]
19. Effects of gonadotrophin-releasing hormone agonist on uterine fibroids and bone density.
Bianchi G; Costantini S; Anserini P; Rovetta G; Monteforte P; Menada MV; Fagà L; De Cecco L
Maturitas; 1989 Sep; 11(3):179-85. PubMed ID: 2512467
[TBL] [Abstract][Full Text] [Related]
20. Buserelin-mediated osteoporosis: effects of restoring estrogen on bone resorption and whole body calcium content in the rat.
Goulding A; Gold E
Calcif Tissue Int; 1990 Jan; 46(1):14-9. PubMed ID: 2104770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
